AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21422847 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 valerate and dienogest
Number of subjects: 180
Study 21422847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 16444091 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor exercise (30 min treadmill walk, 5 days/week at 60% of maximal heart rate)
Number of subjects: 90
Study 16444091 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor exercise (30 min track walking, 5 days/week at 60% of maximal heart rate)
Number of subjects: 90
Study 16444091 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 90
Study 12472488 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Skin Substitute (HSS) applied to 6 patients
Number of subjects: 12
Study 12472488 — intervention group
Group type: COMPARATOR
Intervention: Secondary intention healing applied to 6 patients
Number of subjects: 12
Study 12472488 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Skin Substitute (HSS)
Number of subjects: 12
Study 12472488 — intervention group
Group type: COMPARATOR
Intervention: Secondary intention healing
Number of subjects: 12
Study 12472488 — intervention group
Group type: COMPARATOR
Intervention: Human Skin Substitute (HSS) and Secondary intention healing
Number of subjects: 12
Study 10682566 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,6‐diphosphate
Number of subjects: 20
Study 10682566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 8746044 — intervention group
Group type: EXPERIMENTAL
Intervention: Short chain fatty acids enema (acetate: 60 mmol/L; propionate: 30 mmol/L; n-butyrate: 40 mmol/L) administered twice a day for 14 days (group 1; n = 7)
Number of subjects: 13
Study 8746044 — intervention group
Group type: COMPARATOR
Intervention: Isotonic NaCl enema (group 2; n = 6)
Number of subjects: 13
Study 8746044 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 volunteers, mean age: 27 years)
Number of subjects: 13
Study 2796619 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 10 mg in 10% glucose solution 2 mL + 15 microgram clonidine (Gr.2)
Number of subjects: 60
Study 2796619 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 10 mg in 10% glucose solution 2 mL + 30 microgram clonidine (Gr.3)
Number of subjects: 60
Study 2796619 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 10 mg in 10% glucose solution 2 mL + 45 microgram clonidine (Gr.4)
Number of subjects: 60
Study 2796619 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine 10 mg in 10% glucose solution 2 mL (Control Group)
Number of subjects: 60
Study 101313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0
Study 101313 — intervention group
Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 0
Study 101313 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate
Number of subjects: 0
Study 31761541 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with a dose prescription of 40 Gy in 5 fractions.
Number of subjects: 0
Study 31761541 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized dose constraints and clinical target volume delineation for SBRT.
Number of subjects: 0
Study 29753118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular onabotulinumtoxinA 400 U
Number of subjects: 176
Study 29753118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular onabotulinumtoxinA 200 U
Number of subjects: 176
Study 29753118 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 176
Study 26954978 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin
Number of subjects: 111
Study 26954978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 26564673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation and Confinement (SDC)
Number of subjects: 20
Study 26564673 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual operation
Number of subjects: 20
Study 26564673 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed operation
Number of subjects: 20
Study 26564673 — intervention group
Group type: EXPERIMENTAL
Intervention: High complexity operation
Number of subjects: 20
Study 26564673 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 23349295 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in a specialised out‐patient mood disorder clinic
Number of subjects: 158
Study 23349295 — intervention group
Group type: COMPARATOR
Intervention: Standard out-patient treatment
Number of subjects: 158
Study 19487105 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon (150g three times per week, resulting in a daily consumption of 2.1g of omega-3 long-chain polyunsaturated fatty acids)
Number of subjects: 324
Study 19487105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil capsules (1.3g of omega-3 long-chain polyunsaturated fatty acids per day)
Number of subjects: 324
Study 19487105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod (150g three times per week, resulting in a daily consumption of 0.3g of omega-3 long-chain polyunsaturated fatty acids)
Number of subjects: 324
Study 19487105 — intervention group
Group type: COMPARATOR
Intervention: Control (sunflower oil capsules, no seafood)
Number of subjects: 324
Study 18091010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18091010 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg SAL (D2)
Number of subjects: 30
Study 18091010 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg SAL (D4)
Number of subjects: 30
Study 18091010 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg SAL (D8)
Number of subjects: 30
Study 16541302 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 5187
Study 14700263 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-eruption surgical-orthodontic technique
Number of subjects: 12
Study 11195717 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous visuomotor compensatory tracking task during sleep deprivation
Number of subjects: 4
Study 11195717 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG power changes during drowsiness
Number of subjects: 4
Study 8698447 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (10 to 40 mg/d), with possible addition of enalapril (5 to 20 mg/d) and/or hydrochlorothiazide (12.5 to 25 mg/d)
Number of subjects: 337
Study 8698447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study 1470824 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone administered intra‐vaginally (600 mg/d)
Number of subjects: 272
Study 1470824 — intervention group
Group type: COMPARATOR
Intervention: Progesterone in solution in oil (50 mg/day) administered by intramuscular injection
Number of subjects: 272
Study 6362694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 40
Study 6362694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine with adrenaline 5 micrograms ml‐1
Number of subjects: 40
Study 6362694 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine
Number of subjects: 40
Study 6362694 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine with adrenaline 5 micrograms ml‐1
Number of subjects: 40
Study 31083368 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting both physical activity and screen time recommendations
Number of subjects: 2321
Study 31083368 — intervention group
Group type: COMPARATOR
Intervention: Not meeting both physical activity and screen time recommendations
Number of subjects: 2321
Study 30528686 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDRP + MVP (Atrial preventive pacing and atrial antitachycardia pacing)
Number of subjects: 100
Study 30528686 — intervention group
Group type: COMPARATOR
Intervention: Standard dual-chamber pacing (DDDR)
Number of subjects: 100
Study 26657213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation sessions focusing on memory strategy (10 sessions)
Number of subjects: 65
Study 26657213 — intervention group
Group type: COMPARATOR
Intervention: Active therapy sessions (placebo control)
Number of subjects: 65
Study 24674576 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal treatment (+1.75 add) during the 3-year period in childhood
Number of subjects: 240
Study 24674576 — intervention group
Group type: EXPERIMENTAL
Intervention: Short reading distance in childhood
Number of subjects: 240
Study 24674576 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent on sports and outdoor activities in childhood
Number of subjects: 240
Study 24674576 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent on reading and close work in childhood
Number of subjects: 240
Study 24674576 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching television <3 hours daily
Number of subjects: 240
Study 24674576 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean myopic progression 8 years after age 20-24
Number of subjects: 240
Study 22527106 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus patient support program
Number of subjects: 503
Study 22527106 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 503
Study 22527106 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient centered care questionnaire
Number of subjects: 503
Study 20357369 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 microg 1,25(OH)(2)D(3) daily for 9 months
Number of subjects: 65
Study 20357369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 18556967 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensated Insulin Resistance (CIR)
Number of subjects: 73
Study 18556967 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompensated Insulin Resistance (DIR)
Number of subjects: 73
Study 18556967 — intervention group
Group type: COMPARATOR
Intervention: Normal Insulin Sensitivity (NIS)
Number of subjects: 73
Study 15883215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/d)
Number of subjects: 173
Study 15883215 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (2.7 mg/d)
Number of subjects: 173
Study 15883215 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 173
Study 11817924 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and psychosocial factors (e.g., race, academic rank, depressive symptomatology, self-reported value of health, appearance, and achievement, parenting style)
Number of subjects: 3798
Study 10365063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 50
Study 10365063 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 50
Study 10365063 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 50
Study 8963917 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ingestion of 30 mg of beta-carotene supplements
Number of subjects: 0
Study 1704989 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (M) 100 mg daily
Number of subjects: 12
Study 1704989 — intervention group
Group type: COMPARATOR
Intervention: Cilazapril (C) 2.5 mg daily
Number of subjects: 12
Study 7372828 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertion training
Number of subjects: 26
Study 7372828 — intervention group
Group type: COMPARATOR
Intervention: Delay-control
Number of subjects: 26
Study 31756304 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic findings (secondary/incidental)
Number of subjects: 2075
Study 31756304 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive attitudes towards genetic testing
Number of subjects: 2075
Study 31756304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower education
Number of subjects: 2075
Study 31756304 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher subjective numeracy
Number of subjects: 2075
Study 31756304 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 2075
Study 31756304 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher absolute risk, preventability, reproductive risk, positive attitudes towards genetic testing
Number of subjects: 2075
Study 31756304 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive attitudes towards genetic testing, younger age
Number of subjects: 2075
Study 28455996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg)
Number of subjects: 16
Study 28455996 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50 mg)
Number of subjects: 16
Study 25826479 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 40
Study 25826479 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 23420622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for personality disorders (CBTpd) plus Treatment as Usual
Number of subjects: 106
Study 23420622 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 106
Study 21848799 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (7 weeks treatment)
Number of subjects: 1250
Study 21848799 — intervention group
Group type: COMPARATOR
Intervention: Placebo (7 weeks treatment)
Number of subjects: 1250
Study 20008236 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging new treatment modalities under investigation for relapsed classical Hodgkin lymphoma
Number of subjects: 0
Study 16973256 — intervention group
Group type: EXPERIMENTAL
Intervention: Gosereline (3.6 mg subcutaneous injection monthly)
Number of subjects: 32
Study 16973256 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg daily per os)
Number of subjects: 32
Study 16973256 — intervention group
Group type: COMPARATOR
Intervention: Gosereline
Number of subjects: 32
Study 16973256 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 32
Study 15029004 — intervention group
Group type: EXPERIMENTAL
Intervention: Two days' training on diabetic foot management
Number of subjects: 0
Study 15029004 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11440901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 6 mg x kg(‐1) x min(‐1) for 180 min
Number of subjects: 14
Study 11440901 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucose infusion at 6 mg x kg(‐1) x min(‐1) for 180 min
Number of subjects: 14
Study 11440901 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of id and iv glucose infusion
Number of subjects: 14
Study 10052045 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP tube
Number of subjects: 50
Study 10052045 — intervention group
Group type: COMPARATOR
Intervention: Silicone tube
Number of subjects: 50
Study 8000630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac sodium (Voltarol; Ciba‐Geigy)
Number of subjects: 55
Study 8000630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 2969320 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic ethinylestradiol (EE) + desogestrel (DG)
Number of subjects: 36
Study 2969320 — intervention group
Group type: COMPARATOR
Intervention: Triphasic ethinylestradiol (EE) + levonorgestrel (LNG)
Number of subjects: 36
Study 30663184 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole (100 mg vaginal tablet, once daily for 7 days)
Number of subjects: 111
Study 30663184 — intervention group
Group type: COMPARATOR
Intervention: Salvia officinalis (400 mg vaginal tablet, once daily for 7 days)
Number of subjects: 111
Study 30663184 — intervention group
Group type: COMPARATOR
Intervention: Combination of Salvia officinalis and Clotrimazole (once daily for 7 days)
Number of subjects: 111
Study 29399825 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-Savvy (active condition)
Number of subjects: 215
Study 29399825 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 215
Study 29399825 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 215
Study 27016296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cytological assessment of bone margins (ICAB)
Number of subjects: 102
Study 24148807 — intervention group
Group type: EXPERIMENTAL
Intervention: Active conservative treatment (pelvic floor muscle training and bladder training)
Number of subjects: 747
Study 24148807 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 747
Study 22968556 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-depo
Number of subjects: 594
Study 22968556 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 594
Study 22968556 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil and dalargin
Number of subjects: 594
Study 20437326 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based Cognitive Strategy Training (CST)
Number of subjects: 21
Study 17907482 — intervention group
Group type: EXPERIMENTAL
Intervention: Quell Desensitizer
Number of subjects: 30
Study 17907482 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride solution (Nupro Neutral)
Number of subjects: 30
Study 16037105 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm birth (before 37 completed weeks)
Number of subjects: 512
Study 16037105 — intervention group
Group type: EXPERIMENTAL
Intervention: Babies born before 37 completed weeks but after 32 weeks
Number of subjects: 512
Study 16037105 — intervention group
Group type: EXPERIMENTAL
Intervention: Babies born between 24 and 33 weeks gestation
Number of subjects: 512
Study 10943871 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate, cyclosporin A, and corticosteroids)
Number of subjects: 82
Study 10943871 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (SSZ) alone
Number of subjects: 82
Study 10943871 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 82
Study 9116921 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine
Number of subjects: 0
Study 9116921 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study 8330601 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach to interscalene block
Number of subjects: 0
Study 8330601 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach to interscalene block
Number of subjects: 0
Study 3570867 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula (PF)
Number of subjects: 0
Study 3570867 — intervention group
Group type: COMPARATOR
Intervention: Banked drip breast milk (BBM)
Number of subjects: 0
Study 2461826 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of adenosine 5'-monophosphate (AMP) at the provocation concentration required to produce a 20% fall in FEV1 (PC20)
Number of subjects: 12
Study 2461826 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of 0.9% (w/v) sodium chloride placebo
Number of subjects: 12
Study 2461826 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of the PC20 allergen
Number of subjects: 12
Study 31814306 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-shaped anastomosis
Number of subjects: 39
Study 31814306 — intervention group
Group type: COMPARATOR
Intervention: Circular stapler anastomosis
Number of subjects: 39
Study 31465185 — intervention group
Group type: EXPERIMENTAL
Intervention: TegadermTM (Group T)
Number of subjects: 0
Study 31465185 — intervention group
Group type: EXPERIMENTAL
Intervention: TegadermTM with sticky pad (Group P)
Number of subjects: 0
Study 31465185 — intervention group
Group type: EXPERIMENTAL
Intervention: TegadermTM with Steri‐StripTM (Group S)
Number of subjects: 0
Study 28730884 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial compensation
Number of subjects: 0
Study 28730884 — intervention group
Group type: COMPARATOR
Intervention: Control (no financial compensation)
Number of subjects: 0
Study 25641932 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry bean enriched diet (250 g/day) for 4 weeks
Number of subjects: 46
Study 25641932 — intervention group
Group type: EXPERIMENTAL
Intervention: Navy bean ethanol extract (10%) for 6 weeks
Number of subjects: 46
Study 25641932 — intervention group
Group type: COMPARATOR
Intervention: Self-reported high dry bean intake (≥42 g/day)
Number of subjects: 46
Study 25641932 — intervention group
Group type: COMPARATOR
Intervention: Self-reported low dry bean consumption (<8 g/day)
Number of subjects: 46
Study 23078515 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (E)
Number of subjects: 72
Study 23078515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol (P)
Number of subjects: 72
Study 23078515 — intervention group
Group type: COMPARATOR
Intervention: Glycerine (control)
Number of subjects: 72
Study 22043672 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut-embedding
Number of subjects: 60
Study 22043672 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 60
Study 19358978 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapeutic augmentation (CAT; Sleep Deprivation + Bright Light + Sleep Phase Advance)
Number of subjects: 49
Study 19358978 — intervention group
Group type: COMPARATOR
Intervention: Medication-only (MED) group
Number of subjects: 49
Study 17109618 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 0
Study 17109618 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 0
Study 15279663 — intervention group
Group type: EXPERIMENTAL
Intervention: CMPD patients
Number of subjects: 35
Study 15279663 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS patients
Number of subjects: 35
Study 15279663 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 35
Study 15279663 — intervention group
Group type: COMPARATOR
Intervention: CMPD patients vs Control group
Number of subjects: 35
Study 15279663 — intervention group
Group type: EXPERIMENTAL
Intervention: CMPD patients with marrow fibrosis
Number of subjects: 35
Study 11716099 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin plus methylbenzethonium chloride ointment applied twice a day for 20 days
Number of subjects: 68
Study 11716099 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 68